Autoplaque vs A View LCS
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary focus is on detailed, quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is specifically designed for in-depth assessment of atherosclerotic plaque characteristics to aid in precise heart attack risk prediction and guide treatment strategies. Its workstation-based deployment allows for focused, clinician-reviewable analysis of coronary anatomy and pathology.
View Autoplaque →Choose A View LCS if…
Choose AVIEW LCS if you require a comprehensive AI-powered platform for broad thoracic CT analysis, particularly from a single low-dose CT scan. This tool excels in integrated lung cancer screening with automated nodule detection and Lung-RADS scoring, alongside emphysema quantification and general coronary artery calcification scoring. Its ability to generate automated comprehensive reports and flexible deployment options make it suitable for a wider range of thoracic diagnostic workflows.
View A View LCS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | A View LCS |
|---|---|---|
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker). It can also be integrated into standard reading environments (PACS), RIS (Radiological Information System), or used as a standalone third-party application or web-based application. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
A View LCSTool B offers greater deployment flexibility, including cloud and hybrid solutions, which enhances accessibility and integration into diverse clinical environments. Its emphasis on automating tedious tasks and generating comprehensive reports streamlines workflow, providing a more efficient user experience compared to Tool A's workstation-based deployment.
Clinical Value
A View LCSWhile both tools are FDA-cleared and provide significant clinical value, Tool B offers a broader 'big 3 diseases' screening (lung cancer, COPD, and coronary artery calcification) from a single low-dose CT scan, offering more comprehensive early detection for a wider range of conditions. Studies also indicate Tool B's lower likelihood of misidentifying nodules compared to human radiologists.
Pricing & Value
A View LCSTool B provides some transparency regarding its pricing model, stating it offers one-off payments or subscriptions based on installations or users. In contrast, Tool A's pricing information is not disclosed, making it harder for potential buyers to assess its value proposition upfront.
Enterprise Readiness
A View LCSTool B explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), which are crucial for enterprise adoption in healthcare. Its flexible deployment options (cloud, hybrid, local) and documented integration with various AI platforms and PACS/RIS systems demonstrate a higher level of enterprise readiness compared to Tool A's workstation-based deployment and unspecified compliance.
Innovation
TieBoth tools demonstrate significant innovation in their respective fields. Tool A's rapid and accurate AI-powered quantitative analysis of coronary plaque, capable of performing tasks in seconds that typically take doctors 25-30 minutes, is highly innovative and was licensed by HeartFlow. Tool B's 'CT kernel conversion AI technology' and its comprehensive multi-disease screening from a single low-dose CT also represent substantial innovation in efficiency and diagnostic scope.
Support & Docs
A View LCSTool B's online presence and reseller information provide clearer avenues for support and documentation, including options to request a demo and readily available support documentation through partners. Tool A's documentation is primarily referenced through its user manual in FDA filings, with less transparent access to support resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | A View LCS |
|---|---|---|
| Product Name | Autoplaque | A View LCS |
| Developer/Company | Cedars-Sinai Medical Center: AIM | Coreline Soft Co. |
| Primary Application/Focus | Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. |
| Cardiac Analysis Capabilities | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Measurement of vessel diameter and area. | Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass); Segmentation of major coronary arteries. |
| Other Thoracic Analysis Capabilities | Not specified | Automated lung nodule detection and classification; Nodule volume quantification and measurement (3D); Lung-RADS scoring and reporting; Emphysema analysis and quantification (LAA); Automated comprehensive report generation (PDF, DICOM PDF, SR); CT kernel conversion AI technology. |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and A View LCS.